Skip to Main Content

Paper Details

Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer.
Clin Genitourin Cancer
12
2023
CD3, CD3-expressing T cells, CRS, Cancer, Cytokine release syndrome, IRR, JNJ-081, JNJ-081 IV, JNJ-63898081, Metastatic Castration-Resistant Prostate Cancer, PSA, PSMA, PSMA-expressing tumor cells, Prostate specific membrane antigen, androgen, androgen receptor, infusion-related reaction, mCRPC, metastatic castration-resistance prostate cancer, patients, prostate cancer, taxane
Author NameAffiliation
Kim N Chi
Rahul AggarwalUCSF Helen Diller Family Comprehensive Cancer Center
Neeraj AgarwalHuntsman Cancer Institute, University of Utah
John T Loffredo
Hong Xie
  • 1 - 5

Datasets

Release 1.2